Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 372

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 372
---
isclosure and confidentiality agreements with parties who have access to them, such as our employees and certain third parties, and entering into invention assignment agreements with our employees and consultants that require them to transfer any inventions developed in the course of their work to us. Patents We do not currently have any patents or patent applications directed to the sequences of specific genes or variants of such genes, nor do we rely on any such in -licensedpatent rights of any third party. To date, we have not developed any patentable products. Copyrights The Heritas has copyright is registered in Argentina, Paraguay, Mexico, Dominican Republic, Costa Rica and Panama. The Rewell copyright is registered in Argentina, Mexico, Peru, Chile and Colombia. Services Agreements CIBIC Pursuant to the Commercialization Agreement, we appointed CIBIC, one of our indirect shareholders, as exclusive agent for the commercialization of Heritas Diagnostics tests in Argentina. CIBIC cannot commercialize outside of Argentina without Heritas Argentina’s consent. The Commercialization Agreement’s term is 30 years, which shall be automatically renewed for ten additional years at its term. In addition, CIBIC is not entitled to any of our intellectual property rights, trade secrets, or know -howassociated with the NGS tests. We grant CIBIC an exclusive, royalty -freelicense to use the Heritas brand for marketing NGS tests. Pursuant to the Commercialization Agreement, Heritas Argentina sells NGS tests to CIBIC at a price determined by pre -agreedpricing lists, after which CIBIC resells these NGS tests to its clients. Further, in accordance with the Commercialization Agreement, Heritas Argentina may update the NGS tests pricing lists at its discretion following five business days’ written notice to CIBIC. Heritas Argentina invoices CIBIC for NGS tests monthly. For more information, see “ Risk Factors — Risks Related to Our Business and Strategy — We depend on CIBIC, one of our indirect shareholders, for a substantial part of our revenues, and if the Commercialization Agreement is terminated, our business and results of operations would be materially adversely affected” and “ Certain Company Relationships and Related Party Transactions.” Meyer On January 25, 2021, we entered into a distribution agreement with Meyer Lab S.A. (“Meyer”) in Paraguay pursuant to which we provide clinical genetic diagnostic tests to Meyer. We process and perform the sequencing of samples provided by Meyer and we deliver the results to Meyer. 194